{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T05:57:35Z","timestamp":1773813455934,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,10,25]],"date-time":"2013-10-25T00:00:00Z","timestamp":1382659200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1007\/s00198-013-2533-0","type":"journal-article","created":{"date-parts":[[2013,10,24]],"date-time":"2013-10-24T12:56:13Z","timestamp":1382619373000},"page":"1187-1190","source":"Crossref","is-referenced-by-count":10,"title":["Severe hypocalcemia after denosumab in a patient with acquired Fanconi syndrome"],"prefix":"10.1007","volume":"25","author":[{"given":"H.","family":"Shafqat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. F.","family":"Alquadan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. J.","family":"Olszewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,10,25]]},"reference":[{"key":"2533_CR1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2003-10-3400","volume":"104","author":"CX Ma","year":"2004","unstructured":"Ma CX, Lacy MQ, Rompala JF, Dispenzieri A, Rajkumar SV, Greipp PR, Fonseca R, Kyle RA, Gertz MA (2004) Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma. Blood 104:40\u201342. doi: 10.1182\/blood-2003-10-3400","journal-title":"Blood"},{"key":"2533_CR2","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2265.1995.tb02621.x","volume":"43","author":"BL Clarke","year":"1995","unstructured":"Clarke BL, Wynne AG, Wilson DM, Fitzpatrick LA (1995) Osteomalacia associated with adult Fanconi's syndrome: clinical and diagnostic features. Clin Endocrinol (Oxf) 43:479\u2013490","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2533_CR3","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.rdc.2011.07.004","volume":"37","author":"RK Dore","year":"2011","unstructured":"Dore RK (2011) The RANKL pathway and denosumab. Rheum Dis Clin N Am 37:433\u2013452. doi: 10.1016\/j.rdc.2011.07.004 , vi-vii","journal-title":"Rheum Dis Clin N Am"},{"key":"2533_CR4","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.coph.2005.06.005","volume":"5","author":"PJ Kostenuik","year":"2005","unstructured":"Kostenuik PJ (2005) Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol 5:618\u2013625. doi: 10.1016\/j.coph.2005.06.005","journal-title":"Curr Opin Pharmacol"},{"key":"2533_CR5","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","volume":"423","author":"WJ Boyle","year":"2003","unstructured":"Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337\u2013342. doi: 10.1038\/nature01658","journal-title":"Nature"},{"key":"2533_CR6","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1073\/pnas.95.7.3597","volume":"95","author":"H Yasuda","year":"1998","unstructured":"Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin\/osteoclastogenesis-inhibitory factor and is identical to TRANCE\/RANKL. Proc Natl Acad Sci U S A 95:3597\u20133602","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2533_CR7","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C, Trial F (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756\u2013765. doi: 10.1056\/NEJMoa0809493","journal-title":"N Engl J Med"},{"key":"2533_CR8","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","volume":"48","author":"A Lipton","year":"2012","unstructured":"Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun A, Jun S (2012) Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 48:3082\u20133092. doi: 10.1016\/j.ejca.2012.08.002","journal-title":"Eur J Cancer"},{"key":"2533_CR9","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1002\/jbmr.403","volume":"26","author":"SA Jamal","year":"2011","unstructured":"Jamal SA, Ljunggren O, Stehman-Breen C, Cummings SR, McClung MR, Goemaere S, Ebeling PR, Franek E, Yang YC, Egbuna OI, Boonen S, Miller PD (2011) Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res 26:1829\u20131835. doi: 10.1002\/jbmr.403","journal-title":"J Bone Miner Res"},{"key":"2533_CR10","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/jbmr.1613","volume":"27","author":"GA Block","year":"2012","unstructured":"Block GA, Bone HG, Fang L, Lee E, Padhi D (2012) A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 27:1471\u20131479. doi: 10.1002\/jbmr.1613","journal-title":"J Bone Miner Res"},{"key":"2533_CR11","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","volume":"145","author":"AS Levey","year":"2006","unstructured":"Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F, Chronic Kidney Disease Epidemiology C (2006) Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145:247\u2013254","journal-title":"Ann Intern Med"},{"key":"2533_CR12","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/jbmr.251","volume":"26","author":"R Eastell","year":"2011","unstructured":"Eastell R, Christiansen C, Grauer A, Kutilek S, Libanati C, McClung MR, Reid IR, Resch H, Siris E, Uebelhart D, Wang A, Weryha G, Cummings SR (2011) Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res 26:530\u2013537. doi: 10.1002\/jbmr.251","journal-title":"J Bone Miner Res"},{"key":"2533_CR13","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1053\/j.ajkd.2012.06.019","volume":"60","author":"BB McCormick","year":"2012","unstructured":"McCormick BB, Davis J, Burns KD (2012) Severe hypocalcemia following denosumab injection in a hemodialysis patient. Am J Kidney Dis 60:626\u2013628. doi: 10.1053\/j.ajkd.2012.06.019","journal-title":"Am J Kidney Dis"},{"issue":"756","key":"2533_CR14","first-page":"e751","volume":"31","author":"P Ungprasert","year":"2013","unstructured":"Ungprasert P, Cheungpasitporn W, Srivali N, Kittanamongkolchai W, Bischof EF (2013) Life-threatening hypocalcemia associated with denosumab in a patient with moderate renal insufficiency. Am J Emerg Med 31(756):e751\u2013e752. doi: 10.1016\/j.ajem.2012.11.011","journal-title":"Am J Emerg Med"},{"key":"2533_CR15","first-page":"S1","volume":"113","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group","year":"2009","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 113:S1\u2013S130. doi: 10.1038\/ki.2009.188","journal-title":"Kidney Int Suppl"},{"key":"2533_CR16","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJM200304103481521","volume":"348","author":"CJ Rosen","year":"2003","unstructured":"Rosen CJ, Brown S (2003) Severe hypocalcemia after intravenous bisphosphonate therapy in occult vitamin D deficiency. N Engl J Med 348:1503\u20131504. doi: 10.1056\/NEJM200304103481521","journal-title":"N Engl J Med"},{"key":"2533_CR17","doi-asserted-by":"crossref","first-page":"R45","DOI":"10.1530\/EJE-12-0528","volume":"168","author":"JE Witteveen","year":"2013","unstructured":"Witteveen JE, van Thiel S, Romijn JA, Hamdy NA (2013) Hungry bone syndrome: still a challenge in the post-operative management of primary hyperparathyroidism: a systematic review of the literature. Eur J Endocrinol 168:R45\u2013R53. doi: 10.1530\/EJE-12-0528","journal-title":"Eur J Endocrinol"},{"key":"2533_CR18","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.bone.2013.04.012","volume":"55","author":"F Milat","year":"2013","unstructured":"Milat F, Goh S, Gani LU, Suriadi C, Gillespie MT, Fuller PJ, Teede HJ, Strickland AH, Allan CA (2013) Prolonged hypocalcemia following denosumab therapy in metastatic hormone refractory prostate cancer. Bone 55:305\u2013308. doi: 10.1016\/j.bone.2013.04.012","journal-title":"Bone"},{"key":"2533_CR19","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/BF00584840","volume":"402","author":"H Wald","year":"1984","unstructured":"Wald H, Popovtzer MM (1984) Renal refractoriness to PTH in experimental Fanconi syndrome: evidence for intact adenylate cyclase activation. Pflugers Arch 402:116\u2013119","journal-title":"Pflugers Arch"},{"key":"2533_CR20","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1038\/ki.2011.27","volume":"121","author":"H J\u00fcppner","year":"2011","unstructured":"J\u00fcppner H (2011) Phosphate and FGF-23. Kidney Int Suppl 121:S24\u2013S27. doi: 10.1038\/ki.2011.27","journal-title":"Kidney Int Suppl"},{"key":"2533_CR21","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.bone.2006.01.163","volume":"39","author":"I Stewart","year":"2006","unstructured":"Stewart I, Roddie C, Gill A, Clarkson A, Mirams M, Coyle L, Ward C, Clifton-Bligh P, Robinson BG, Mason RS, Clifton-Bligh RJ (2006) Elevated serum FGF23 concentrations in plasma cell dyscrasias. Bone 39:369\u2013376. doi: 10.1016\/j.bone.2006.01.163","journal-title":"Bone"},{"key":"2533_CR22","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1007\/s00774-011-0262-z","volume":"29","author":"T Kitaoka","year":"2011","unstructured":"Kitaoka T, Namba N, Miura K, Kubota T, Ohata Y, Fujiwara M, Hirai H, Yamamoto T, Ozono K (2011) Decrease in serum FGF23 levels after intravenous infusion of pamidronate in patients with osteogenesis imperfecta. J Bone Miner Metab 29:598\u2013605. doi: 10.1007\/s00774-011-0262-z","journal-title":"J Bone Miner Metab"},{"key":"2533_CR23","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","volume":"29","author":"DH Henry","year":"2011","unstructured":"Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29:1125\u20131132. doi: 10.1200\/JCO.2010.31.3304","journal-title":"J Clin Oncol"},{"key":"2533_CR24","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1182\/blood-2012-10-435750","volume":"121","author":"E Terpos","year":"2013","unstructured":"Terpos E, Roodman GD, Dimopoulos MA (2013) Optimal use of bisphosphonates in patients with multiple myeloma. Blood 121:3325\u20133328. doi: 10.1182\/blood-2012-10-435750","journal-title":"Blood"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-013-2533-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-013-2533-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-013-2533-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T11:08:57Z","timestamp":1558609737000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-013-2533-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,25]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["2533"],"URL":"https:\/\/doi.org\/10.1007\/s00198-013-2533-0","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,25]]}}}